28 feb: Meddelelse#91 ? Mermaid forfremmer Mads Henrik Hansen
01 mar: SKAGEN Fondene henter Tryg direktør Ole Søeberg
01-03-2011 09:00:00

Cerner Fulfills CE Marking Requirements for Medical Device Connectivity Solution

Cerner CareAware iBus Solution Approved to be Offered in the European Union

KANSAS CITY, Mo., 2011-03-01 09:00 CET (GLOBE NEWSWIRE) --Cerner Corporation today announced that the CareAware iBus has received CE

Marking certification from BSI on the basis of examination under Council

Directive 93/42/EEC Annex II Section 3.2.

The Cerner CareAware iBus solution connects important medical device

information about patient health from disparate systems to the patient's

electronic health record (EHR). This solution will be immediately available to

healthcare organizations in the EU allowing them to access medical information

from medical devices and EHRs to make informed care decisions.

"As a global leader in the development of device connectivity and workflow

solutions, we are excited to extend the offering of our CareAware iBus solution

into the European market," said Tom Herzog, Cerner vice president for IT and

healthcare devices. "Connecting medical devices to the patient's EHR supports

healthcare interoperability, enabling patients and caregivers to access the

right information at the right time."

The Cerner CareAware iBus solution works to improve clinician workflow and

patient safety by:

-- Reducing time spent manually transcribing device data into the EHR,

allowing clinicians to spend more time on direct patient care;

-- Decreasing the chance of medication errors by virtually eliminating manual

data entry errors and increasing the accuracy of data;

-- Providing the ability to automatically perform calculations on medical

device data, including trending capabilities for various sources of

information like heart rate and blood pressure;

-- Reducing interface implementation and maintenance costs through efficient

management of medical device deployment; and

-- Improving monitoring abilities of device performance, connectivity status

and device utilization.

The Cerner CareAware iBus solution provides additional functionality and

workflow benefits. Plug-and-play capabilities for connecting medical devices to

any EHR system allow medical devices to connect to the Cerner CareAware iBus

much like a USB port that quickly and easily connects peripheral devices to a

computer. Once a device is connected, it is immediately recognized and can

begin transmitting patient data to the EHR. The solution also allows waveform

data to be transmitted directly into the EHR. Clinicians may then analyze the

patient's device data in the context of other clinically relevant data for a

specific time period, enabling them to make the best informed care decisions

with all relevant information easily accessible from multiple medical devices.

About Cerner

Cerner is transforming healthcare by eliminating error, variance and waste for

healthcare providers and consumers around the world. Cerner® solutions optimize

processes for healthcare organizations ranging in size from single-doctor

practices, to health systems, to entire countries, for the pharmaceutical and

medical device industries, employer health and wellness services industry and

for the healthcare commerce system. These solutions are licensed by

approximately 9,000 facilities around the world, including more than 2,600

hospitals; 3,500 physician practices covering more than 30,000 physicians; 500

ambulatory facilities, such as laboratories, ambulatory centers, cardiac

facilities, radiology clinics and surgery centers; 800 home health facilities;

and 1,600 retail pharmacies. The trademarks, service marks and logos

(collectively, the "Marks") set forth herein are owned by Cerner Corporation

and/or its subsidiaries in the United States and certain other countries

throughout the world. Nasdaq:CERN. For more information about Cerner, please

visit www.cerner.com, Twitter, Facebook, and YouTube .

CONTACT: Cerner Media Contact:

Kelly Johnson

+1-816-777-8466

kelly.johnson@cerner.com

Cerner Investors Contact:

Allan Kells

+1-816-201-2445

akells@cerner.com

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
10 dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
26
08 dec
ZEAL
Der er et stykke historie omkring Zealand Pharma som jeg ikke har set nogen analytikler eller andre ..
23
07 dec
VWS
Hold nu. Nu er de støjende skribenter endelig sendt i karantæne og der er en helt anden ro i debatte..
19
10 dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
18
10 dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
16
07 dec
VELO
Lidt spændende læsning og et overblik over det kæmpe potentiale som ligger i Veloxis.    https://www..
16
06 dec
 
Baronen, du har længe haft Bitcoin siger du? Men har først nævnt det herinde 13/10-2017?   Tror du v..
15
11:53
BAVA
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
14
09 dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
14
07 dec
VWS
Lyt til amerikanerne. De ved trods alt hvad de taler om. Alle er vel enige om at PTC fortsætter uæn..
14

Genmab/IR: Royalties vil som minimum dække omkostningerne næste år

12-12-2017 14:04:43
Genmabs royaltyindtægter fra salget af selskabets kræftmidler vil i 2018 som minimum dække omkostningerne.Det præciserer Genmabs IR- og kommunikationsdirektør, Rachel Curtis Gravesen, i en e-mail over for Ritzau Finans, efter at selskabet i nattens løb er kommet med en foreløbig prognose for 2018, som angiveligt har givet anledning til en del tolkning i analytikerkredse vedrørende salget af Genmab..

Aktier/middag: Genmab ryger ned på usikkerhed om 2018-forventninger

12-12-2017 11:39:38
Genmab er under hårdt pres på det danske aktiemarked tirsdag, da flere investorer har tolket negativt på ledelsens udmeldinger om 2018 og nu regner med et lavere salg af kræftmidlet Darzalex end tidligere.Aktien dykker 7,7 pct. til 1093 kr. - det største fald i små to år - og nedturen for biotekaktien er med til at tynge C20 Cap-indekset, som dykker 0,3 pct. til 1125,54.Genmab afholdt natten til t..

Aktier/tendens: SAS klar med endelige regnskabstal før handelsstart

12-12-2017 08:15:47
Luftfartsselskabet SAS offentliggjorde forud for børsåbningen tirsdag sit endelige regnskab for det skæve regnskabsår 2016/17, og selskabet kan derfor løbe med en del af opmærksomheden ved handelsstart.Det danske aktiemarked kan gå endnu en grøn dag i møde på det ledende eliteindeks, hvis den amerikanske grønne bølge forplanter sig på de europæiske markeder.Mandag fik C20 Cap-indekset en positiv s..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Genmab/Jefferies: Svært at se væsentlig konkurrencerisiko
2
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen
3
Genmab-aktien får kurstæsk efter forsigtig udmelding fra ledelsen - NY
4
Novo-rival for godkendt kopiprodukt
5
Ørsted opjusterer forventninger efter delvist salg af havmøllepark -NY

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
12. december 2017 17:09:57
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-12 17:09:57 - 2017-12-12 17:09:57 - 1 - Website: OKAY